Market Overview

iSchemaView RAPIDTM Technology Now Installed in More Than 500 Stroke Centers — up 48 Percent Since April

Share:

Explosive Growth of the De Facto Standard for Advanced
Cerebrovascular Imaging

iSchemaView, the leader in cerebrovascular imaging analysis, today
announced accelerated adoption of the RAPID advanced imaging platform.
Over 575 stroke centers in 22 countries around the world have now
committed to using the RAPID platform, with 520 currently installed.
RAPID technology assists physicians in the analysis of brain images
using automated tools for CT ASPECTS, CT angiography, CT perfusion, MR
diffusion and perfusion for more than 85,000 stroke cases per year.
RAPID is also currently deployed in six multi-center clinical trials
globally — adding 200 hospitals to RAPID's global reach.

"Stroke centers want the very best technology to improve patient
outcomes, and RAPID's reputation as the platform of choice for stroke
research has accelerated the pace of our growth tremendously," said Don
Listwin, CEO of iSchemaView. "The fast growth of the RAPID platform —
the only next-generation imaging platform validated in multiple clinical
trials — means a substantial increase in the number of addressable
patients who have suffered ischemic stroke."

Under IRB approval, iSchemaView's RAPID platform was recently used to
select patients for two landmark stroke trials published in The New
England Journal of Medicine
, DAWN and DEFUSE 3, that successfully
treated patients up to twenty-four hours after onset. RAPID was the
exclusive imaging tool used to aid in patient selection in both studies.
The results of the studies helped change the American Heart Association
and American Stroke Association's stroke guidelines to include CT
perfusion and MR perfusion.

The prior treatment window for mechanical thrombectomy was up to six
hours. Starting in 2018, select patients with salvageable brain tissue
identified through advanced imaging are now eligible for treatment up to
twenty-four hours after they were last seen well.

"In addition to individual stroke centers, iSchemaView's RAPID platform
has recently been adopted by several large hospital systems, including
17 hospitals of Baylor Scott & White Health," said Anil Singhal, MD,
Senior Vice President for iSchemaView. "By deploying RAPID through large
hospital systems in a hub and spoke model, more patients will be able to
get the right treatment at the most appropriate facility, vastly
improving patient care and at the same time increasing hospital
efficiency."

The RAPID neuroimaging platform creates high-quality images from
non-contrast CT, CT angiography, CT perfusion and MRI diffusion and
perfusion studies. The software provides an intuitive and easily
interpretable real-time view of brain perfusion, allowing physicians to
determine lesion volumes for a wide variety of different thresholds. The
platform includes four different imaging products, tailored to the
particular needs of each facility:

  • RAPID MRI provides fully automated, easy-to-interpret diffusion
    and perfusion maps that identify brain areas with low ADC values, as
    well as delayed contrast arrival. RAPID MRI perfusion automatically
    quantifies regions of reduced cerebral blood flow, volume and transit
    time that exceed pre-specified thresholds.
  • RAPID CTP provides perfusion maps that automatically quantify
    regions of reduced cerebral blood flow, volume and transit time that
    exceed pre-specified thresholds. Regions are color coded, and the
    volumes of interest are automatically measured. Maps (including
    mismatch maps) of the severity of Tmax delays are provided using a
    four-color-coded scale.
  • RAPID CTA automatically provides clear, easy-to-interpret CTA
    maps which include a colored overlay to identify brain regions with
    reduced blood vessel density. The severity of reduction can be readily
    visualized by a simple four-color-coded scale. Additionally, a 3D
    reconstruction of the vasculature allows physicians to rotate the
    image for optimal viewing of the vessels from multiple angles.
  • RAPID ASPECTS automatically generates a standardized score —
    based on clinically validated machine learning algorithms — that
    enables physicians to easily communicate about the extent of a
    patient's ischemic changes and to determine eligibility for
    thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear
    visualization of the brain so that clinicians can better scrutinize
    each region and confirm the automated score. RAPID ASPECTS is CE
    Marked.

About iSchemaView

iSchemaView is the leader in cerebrovascular imaging analysis,
delivering the proven software tools that healthcare professionals
around the world use to successfully identify and treat more stroke
patients than ever before. Already installed in over 500 hospitals and
stroke centers, iSchemaView's RAPID (automated CTP, MR, CTA and ASPECTS)
is the most advanced brain imaging platform. In clinical trials, under
IRB, RAPID has been shown to aid in the selection of patients in early
and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN
and DEFUSE 3. In addition to achieving the best clinical outcomes
and largest treatment effects ever obtained, these landmark studies led
to new American Heart Association and American Stroke Association
guidelines and have dramatically altered the management of acute stroke
around the world. For more information, visit www.iRAPID.com.

View Comments and Join the Discussion!